Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease

F F di Mola, H Friess, Z W Zhu, A Koliopanos, T Bley, P Di Sebastiano, P Innocenti, A Zimmermann, M W Büchler

Abstract

**Background**—Nerve growth factor (NGF), a target derived factor for survival and maintenance of peripheral and central neurones, has been implicated in several chronic inflammatory processes.

**Aims**—To analyse the concomitant presence of NGF and its high affinity receptor TrkA in patients undergoing surgery for Crohn’s disease (CD) and ulcerative colitis (UC).

**Patients**—CD tissues were obtained from 33 patients and UC tissue samples from 12 patients undergoing surgery. Normal intestinal tissue samples were obtained from 30 individuals through an organ donor programme.

**Methods**—Expression of NGF and TrkA was studied by northern blot analysis. Using in situ hybridisation and immunohistochemistry, the respective mRNA moieties and proteins were localised. Western blot analysis was used to confirm the specificity of NGF and TrkA antibodies.

**Results**—In CD, NGF mRNA was increased in 60% (2.4-fold; p<0.01) and TrkA mRNA in 54% (1.3-fold; p<0.05) of samples. In UC, NGF mRNA expression was enhanced in 58% (2.4-fold; p<0.01) and TrkA mRNA expression in 50% (1.5-fold; p<0.05) of samples. In situ hybridisation showed that NGF and TrkA mRNA were often concomitantly present in polymorphonuclear-like cells of the lamina propria, in mast cells, and in a few ganglia of Auerbach’s plexus and Meissner’s plexus. Immunohistochemistry revealed that lamina propria cells and inflammatory cells (mainly mast cells) were NGF and TrkA immunopositive. NGF was also present in Meissner’s plexus (especially in CD) and TrkA in enteric glia surrounding intestinal ganglia.

**Conclusions**—The concomitant enhanced expression of NGF and its receptor suggests activation of this pathway in chronic inflammation in CD and UC. The presence of NGF and TrkA in both neural and non-neural structures in CD and UC supports the hypothesis that neuro-immune interactions occur and are activated in both disorders.

(Gut 2000;46:670–678)

Inflammatory bowel disease (IBD) comprises primarily two disease states: Crohn’s disease (CD) and ulcerative colitis (UC). Recent neurobiology studies have demonstrated involvement of the enteric nervous system during intestinal inflammation in humans and in different animal models. However, abnormalities of the enteric nervous system are a common finding in patients with IBD and were first postulated to have a role in its pathogenesis almost 50 years ago. They are more characteristic of CD than UC and include both proliferative and degenerative changes. In CD, morphological changes in the innervation pattern consisting of widespread alterations of the gut autonomic nervous system have been described. These include hypertrophy of nerve plexus, hyperplasia of ganglion cells, and ultrastructural axonal degeneration, all summarised as “neuromatous hyperplasia”. Similar but less evident alterations have been reported in the colonic myoneural plexus of longstanding UC, also suggesting that nerve alterations may modulate the inflammatory response.

The molecular mechanisms involved in chronic intestinal inflammation and in alterations of the enteric nervous system in IBD are unclear. However, there is increasing evidence for mediators participating in changes in the enteric nervous system in these disorders. Recent preliminary studies have demonstrated that neurotrophins—such as nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and neurotrophin—3—are abundantly expressed in the inflamed colon of different animal models of IBD and in human CD and UC tissue samples. In addition, there is immunohistochemical evidence that nerve growth factor receptor is increased in CD although the antibody used was not well defined. Inasmuch as NGF may influence peripheral and the phenotype of different peripheral sensory and sympathetic nerves, these findings suggest a potential role for NGF and its receptor in the maintenance of the enteric nervous system and in changes which occur during intestinal inflammation.

NGF is produced by a range of cell types in response to different cytokines. Interleukin 1β

**Abbreviations used in this paper:** NGF, nerve growth factor; CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; BDNF, brain derived neurotrophic factor; PDGF, platelet derived growth factor; FGF, fibroblast growth factor; TNF-α, tumour necrosis factor α; EGF, epidermal growth factor; TGF, transforming growth factor; SP, substance P; CGRP, calcitonin gene related peptide.
NGF and TrkA expression in inflammatory bowel disease introduces NGF synthesis in smooth muscle cells while in fibroblasts NGF synthesis is increased in response to interleukin 1β, platelet derived growth factor (PDGF), acidic or basic fibroblast growth factor (FGF), tumour necrosis factor (TNF) α, epidermal growth factor (EGF), and transforming growth factor (TGF)-α and -β. Furthermore, CD4+ T lymphocytes and mast cells express NGF and its high affinity receptor TrkA, suggesting a possible interaction between the immune and neural systems in chronic inflammation. NGF signalling is mediated via binding to high and low affinity receptors. The high affinity receptor is called TrkA and signalling is transmitted via an internal tyrosine-kinase domain. p75, the low affinity receptor of NGF, belongs to the G protein receptor family and plays a minor role in signal transduction. A recent study demonstrated that the responsiveness of NGF may be conferred by a single interaction of NGF with TrkA. TrkA is present in dorsal root and peripheral ganglia cells of primary sensory nerves and is involved in signal transduction of noxious stimuli and tissue injury. Inflammation results in an increase in NGF levels. NGF may itself have cytokine-like functions; it can modify mast cell, macrophage, and B cell functions but may also activate TrkA located on sensory and sympathetic nerve fibres innervating the site of inflammation, thus modulating neuroimmune interactions.

In this study our aim was to analyse and locate concomitant gene expression of NGF and its high affinity receptor TrkA in CD and UC to further evaluate their potential role in the pathophysiology of these complex diseases.

**Methods**

**PATIENTS**

Normal human intestinal tissue samples were obtained from 30 patients (11 females, 19 males; median age 48 years; range 15–55) through an organ donor programme in which other organs were taken for organ transplantation. CD tissues were obtained from 33 patients (15 females, 18 males; median age 40.7 years; range 16–70) undergoing elective surgery by clinical follow up. In the case of CD, disease severity was assessed preoperatively according to the simple index of Crohn’s disease activity (CDAI) described by Best and colleagues and the activity index (AI) described by Van Hess and colleagues. Both indices showed active disease in all patients.

**TISSUE SAMPLING**

Immediately on surgical removal, normal, CD, and UC tissue samples were fixed in Bouin’s solution or paraformaldehyde for 12–24 hours and embedded in paraffin for histological analysis. Simultaneously, a randomly selected part of the resected tissue samples which was destined for RNA extraction was snap frozen in the operating room in liquid nitrogen and maintained at −80°C until use. The studies were approved by the Human Subjects Committee of the University of Bern, Switzerland.

**PROBE SYNTHESIS**

The NGF cDNA probe consisted of a 313 base pair (bp) KspI/SpeI fragment of mouse NGF cDNA. The TrkA cDNA probe consisted of a 401 bp SacI/KspI fragment of human TrkA cDNA. The identity of the cDNA fragments was sequenced using the dye terminator method as reported previously (ABI 373A, Perkin Elmer Rot Kreuz, Switzerland). A 190 bp BamHI/BamHI fragment of mouse 7S cDNA that cross hybridises with human 7S RNA was used to verify equivalent RNA loading in northern blot experiments. NGF and TrkA cDNA fragments were subcloned into the pGEM-T Easy as previously reported. The 7S cDNA probe was subcloned into the pGEM 7ZF(+) vector (Promega, Biotechnology, Madison, Wisconsin, USA).

For northern blot analysis the cDNA (7S) and cRNA (NGF and TrkA) probes were radioactively labelled with [α-^32P]dCTP and [α-^32P]dCTP, respectively (Du Pont Boston, Massachusetts, USA). For in situ hybridisation analysis, sense and antisense cRNA probes of NGF and TrkA were labelled with digoxigenin as reported previously.

**NORTHERN BLOT ANALYSIS**

Following RNA extraction and gel electrophoresis, RNA was electrotransferred onto nylon membranes (Gene Screen, Du Pont, Boston, Massachusetts, USA) and cross linked by UV irradiation. The filters were then prehybridised, hybridised, and washed under conditions appropriate for ^32P-labelled antisense cRNA riboprobes (NGF and TrkA) or cDNA probes (7S) as previously reported.

Membranes were then exposed at −80°C to Fuji x ray films with intensifying screens and the intensity of the radiographic bands was quantified using a computerised video system and Image-Pro Plus 3.0 software (Media Cybernetics, Silver Spring, Maryland, USA). All membranes were rehybridised with the 7S cDNA probe to assess equivalent RNA loading as previously reported. Data are expressed as the ratio of the NGF and TrkA mRNA signals divided by the corresponding 7S signals.

**IN SITU HYBRIDISATION**

In situ hybridisation was performed according to a modified version of the protocol described previously. Briefly, five consecutive tissue sections (4 µm) of each tissue sample were...
permeabilised with proteinase K (Boehringer Mannheim, Mannheim, Germany), prehybridised, and then hybridised overnight at 65°C (NGF) and 66°C (TrkA). After hybridisation, excess probe was removed by washing in 2X SSP/5 mM EDTA and by RNase treatment at 37°C for 30 minutes. After washing for 20 minutes in 2X SSP/5 mM EDTA at 65°C (NGF) and 68°C (TrkA) and for 20 minutes in 0.2X SSP/5 mM EDTA under the same stringent conditions, the tissue sections were incubated with an antidigoxigenin antibody conjugated with alkaline phosphatase (Boehringer Mannheim, Mannheim, Germany). For the colour reaction, 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (Sigma, Buchs, Switzerland) were used.

### Table 1 Summary of immunohistochemical and in situ hybridisation findings in Crohn’s disease and ulcerative colitis

<table>
<thead>
<tr>
<th></th>
<th>Immunohistochemistry</th>
<th>In situ hybridisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NGF</td>
<td>TrkA</td>
</tr>
<tr>
<td><strong>Crohn’s disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamina propria cells</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Auerbach plexus</td>
<td>++/+</td>
<td>–</td>
</tr>
<tr>
<td>Meissner plexus</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>Glia cells</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>–/–</td>
<td>–/–</td>
</tr>
<tr>
<td>Mast cells</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td><strong>Ulcerative colitis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamina propria cells</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Auerbach plexus</td>
<td>++/+</td>
<td>–</td>
</tr>
<tr>
<td>Meissner plexus</td>
<td>++/+</td>
<td>–</td>
</tr>
<tr>
<td>Glia cells</td>
<td>–/–</td>
<td>–/–</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>–/–</td>
<td>–/–</td>
</tr>
<tr>
<td>Mast cells</td>
<td>+++</td>
<td>+++</td>
</tr>
</tbody>
</table>

−, No signal; +, weak signal; ++, moderate signal; ++++, intense signal.

**IMMUNOHISTOCHEMISTRY**

Paraffin embedded tissue sections (2–4 μm thick) were subjected to immunostaining using the streptavidin-peroxidase technique (Kirkegaard and Perry Laboratories, Gaithersburg, Maryland, USA). Five consecutive tissue sections for each tissue sample were submerged for 15 minutes in Tris buffered saline (TBS) (10 mM Tris HCl, 0.85% NaCl, pH 7.4) containing 0.1% (vol/vol) Triton X-100 and then washed for five minutes in TBS solution as previously reported.20 21 Endogenous peroxidase activity was quenched by incubating the slides in methanol and methanol/0.6% hydrogen peroxide followed by washings in methanol and TBS containing 0.1% bovine serum albumin.22 23 The sections were then incubated for 30 minutes at 23°C with 10% normal goat serum and incubated overnight at 4°C with primary antibodies diluted in 10% normal goat serum as follows: polyclonal anti-NGF (Santa Cruz Biotechnology, Santa Cruz, California, USA) (1:500 dilution) to detect the mature form of the NGF peptide; polyclonal anti-TrkA (TrkA immunoglobulin) (Santa Cruz Biotechnology) epitope corresponding to amino acids 763–777 mapping adjacent to the carboxy terminus of human Trk p140 (1:1000 dilution) and not cross reactive with Trk-B or Trk-C. Furthermore, a polyclonal anti-PGP 9.5 (Ultrade-clone Ltd, Isle of Wight, UK) (1:1000 dilution) antibody, which is well characterised as a panneuronal marker, was used. Bound antibody was detected with a biotinylated goat antirabbit IgG secondary antibody and a streptavidin-peroxidase technique (Kirkegaard and Perry Laboratories) followed by incubation with diaminobenzidine tetrahydrochloride (0.05%) as the substrate and counterstaining with Mayer’s haematoxylin. To ensure antibody specificity, control slides were incubated either in the absence of primary antibody or with a non-specific IgG antibody. In both cases no immunostaining was detected. In addition, tissue sections obtained from normal intestine, CD, and UC were processed with Giemsa staining to stain mast cells.

All slides were analysed by two independent observers blinded to patient status, followed by resolution of any differences by joint review and consultation with a third observer.

**WESTERN BLOT ANALYSIS**

Proteins were extracted from approximately 200 mg of frozen tissues. Protein concentrations were measured with the micro BCA protein assay (Pierce, Rockford, Illinois, USA). From each sample 40 μg of protein were separated on 12% (NGF) and 7% (TrkA) SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes. Nitrocellulose membranes were incubated in blocking solution (3% non-fat milk in 20 mM Tris HCl, 150 mM NaCl, 0.1% Tween-20 (TBS-T)) followed by incubation with polyclonal anti-NGF antibodies (1:1600) (Santa Cruz Biotechnology) and anti-TrkA (1:10 000) (Santa Cruz Biotechnology) for one hour at room temperature. The membranes were then washed with TBS-T and incubated with a horseradish
peroxidase conjugated donkey antirabbit IgG (1:1000 dilution) for 30 minutes at room temperature. Antibody detection was performed with an enhanced chemiluminescence reaction (ECL western blotting detection, Amersham Life Science, Amersham, UK).

**COMPARISON OF MOLECULAR DATA WITH CLINICOPATHOLOGICAL FINDINGS**

In the tissue samples with increased NGF and/or TrkA mRNA levels, molecular data were compared with clinicopathological parameters to determine if the increased gene expression in these samples was clinically significant. In this analysis, duration of disease, presence of fistulae and/or stenosis at the time of surgery, activity index, leucocyte level, and C-reactive protein values were included. Because of the low number of tissue samples with increased expression of NGF and/or TrkA in patients with UC, this analysis was not performed.

**STATISTICAL ANALYSIS**

Results are expressed as median (range). For statistical analysis the Mann-Whitney test and Spearman test were used. Significance was defined as p<0.05.

**Results**

**NORTHERN BLOT ANALYSIS**

Northern blot analysis of 20 µg of total RNA was performed to determine the level of expression of NGF and TrkA mRNA in normal intestinal, CD, and UC tissue samples.

**Figure 2** In situ hybridisation of NGF (A, C, E) and TrkA (B, D, F) mRNA expression in consecutive tissue sections of normal intestine (A, B), and in samples from patients with Crohn’s disease (CD) (C, D) and ulcerative colitis (UC) (E, F). Strong NGF and TrkA mRNA signals often co-localised in polymorphonuclear-like cells of the lamina propria, especially close to the mucosal surface in both CD and UC. The inserts show ganglia of Auerbach’s plexus with weak to moderate mRNA signals for NGF (A, C, E) and TrkA (B, D, F). Arrows indicate the positive signals. Original magnification ×200; insert ×400.
Low levels of NGF (transcript size 1.3 kilobases) and TrkA (transcript size 3.2 kilobases) mRNA were observed in normal intestinal tissue samples (fig 1A, B). In 60% of the CD tissue samples there was a marked increase in NGF mRNA levels. TrkA mRNA levels were increased in 54% of the CD tissue samples. Densitometric analysis of the northern blots indicated that compared with the normal intestine there were 2.4- and 1.3-fold increases in NGF (p<0.01) and TrkA (p<0.05) mRNA levels, respectively, in these CD tissue samples (fig 1A).

In UC tissue samples, NGF mRNA expression was increased in 58% of samples and TrkA mRNA levels in 50% of samples. Densitometric analysis of the levels of expression in these UC samples revealed 2.4- and 1.5-fold increases in mRNA gene expression for NGF (p<0.01) and TrkA (p<0.05) (fig 1B).

In the subgroup of CD and UC tissue samples with increased mRNA expression, NGF and TrkA mRNA expression were concomitantly increased in 50% of CD and 71% of UC samples.

IN SITU HYBRIDISATION

In situ hybridisation was performed to determine the exact site of NGF and TrkA mRNA synthesis (table 1). Five consecutive tissue sec-

Figure 3 Haematoxylin and eosin staining (A), Giemsa staining (B), in situ hybridisation of NGF (C), and TrkA (D), and immunohistochemistry of NGF (E) and TrkA (F) in mast cells in tissue sections from patients with Crohn’s disease (CD). Moderate to strong in situ hybridisation signals (C, D) and a comparable pattern of immunostaining (E, F) of NGF (C, E) and TrkA (D, F) were found in mast cells. Original magnification ×400.
tions of each tissue sample from normal intestinal, CD, and UC tissue samples were always processed simultaneously.

In the normal intestine obtained from organ donors, weak NGF (fig 2A) and TrkA (fig 2B) mRNA signals were found. The signals were located in only very few lamina propria cells (mainly polymorphonuclear-like cells) and in some ganglia of Auerbach’s intermuscular plexus (insert in fig 2A, B). Epithelial cells and muscle cells were devoid of NGF or TrkA mRNA signals. In contrast with the normal intestine, CD (fig 2C, D) and UC (fig 2E, F) tissue samples, which exhibited high levels of mRNA expression by northern blot analysis, also showed intense mRNA staining with in situ hybridisation. In both CD (fig 2C) and UC (fig 2E) tissue samples, NGF mRNA signals were present primarily in high rates in polymorphonuclear-like cells in the lamina propria and in mast cells (fig 3C) invading the whole intestinal wall. These findings were more evident in the area of severe damage and especially in the proximity of the mucosal surface (fig 2C, E). A few ganglia cells of the Meissner plexus and Auerbach’s plexus exhibited weak to moderate NGF mRNA signals, particularly in CD (insert in fig 2C). Very weak NGF mRNA signals were present in the remaining intact epithelial cells of CD and UC samples (fig 2C, E). TrkA mRNA signals were often found in the same cell types that expressed NGF in both CD (fig 2D; fig 3D) and UC (fig 2F) tissue sections. In addition, weak to moderate TrkA signals were found in endothelial cells in both CD and UC tissue samples.

In situ hybridisation using DIG labelled sense probes corresponding to the antisense probes failed to produce signals (data not shown).

**IMMUNOHISTOCHEMISTRY**

Using consecutive sections, immunohistochemistry was performed to localise NGF and TrkA in CD and UC tissue samples (table 1). PGP 9.5 immunostaining was used to visualise the intrinsic nervous system by staining consecutive tissue sections of normal (fig 4A), CD (fig 4D), and UC (fig 4G) tissue samples. In contrast with the normal intestine (fig 4B, C), in CD (fig 4E) and UC (fig 4H) intense concomitant immunostaining was found in the polymorphonuclear-like cells in the lamina propria close to the luminal surface. The inserts show NGF immunoreactive ganglia of Auerbach’s plexus in the normal intestine (B, arrows indicate ganglia), CD (E), and UC (H). TrkA immunoreactivity was found mainly in the glia cells in the normal intestine (insert G, arrows), in CD (insert F, arrows), and in UC (insert I). The slides are counterstained with haematoxylin. Original magnification ×200; insert ×400.
samples (fig 5). Western blot analysis confirmed the specificity of NGF and TrkA antibodies. The NGF antibody detects an approximately 14.4 kDa protein and the TrkA a 140 kDa protein as reported previously (fig 5).24

**Comparison of NGF and TrkA Gene Expression with Clinico pathological Characteristics**

To determine if expression of NGF and/or TrkA in CD was clinically significant, the northern blot data were compared with some clinico pathological parameters (table 2).

In CD tissue samples there was a significant negative association between NGF mRNA levels and the presence of CD related complications (fistulae and/or stenosis) at the time of surgery ($r=-0.6; p<0.05$). However, there was no correlation between NGF mRNA levels and duration of disease, CD activity index, leucocyte level, or C-reactive protein levels.

Moreover, the negative relationship between the concomitant presence of NGF and TrkA mRNA and the presence of CD related complications was much stronger ($r=-0.94; p<0.01$) than when the analysis was performed for NGF alone (table 2).

**Discussion**

In this study we found that expression of NGF and its signalling high affinity receptor TrkA were increased in the inflamed intestines of patients undergoing surgery for CD and UC compared with normal intestinal tissue samples. Many of the CD and UC tissue samples exhibited concomitant enhanced expression of NGF and TrkA mRNA, indicating activation of the NGF/TrkA signalling pathway in IBD. Using in situ hybridisation, we found that NGF and TrkA mRNA often co-localised in lamina propria cells, in inflammatory cells invading the intestinal wall (especially in CD), and in a few ganglia of the Auerbach plexus and Meissner’s plexus. In addition, immunohistochemistry revealed intense NGF and TrkA immunoreactivity mainly in the Auerbach plexus and Meissner’s plexus, which were often increased in number and size,56 and in the lamina propria cells—especially in those close to the luminal surface. In addition, in CD and UC, intense NGF and TrkA mRNA and protein signals were present in mast cells which had infiltrated the intestinal wall. Our data, demonstrating the presence of NGF and its high affinity receptor TrkA in both neural and non-neural structures in CD and UC, further support the hypothesis that the enteric nervous system is involved to some extent in the pathophysiology of IBD, and provide evidence for a “neuroimmune interaction” in these disorders.

Nerves in peripheral adult tissues are often considered to be a stable element with a low potential for remodelling and adaptation. Interestingly, Stead et al have demonstrated that inflammatory cells such as mast cells located in the lamina propria of the gut are in close contact with the enteric nerves thus demonstrating the anatomical connection between the enteric nerves and inflammatory cells.57 In addition, it has been reported that sensory

---

**Table 2 Clinicopathological Comparison of Expression of NGF, TrkA, and NGF/TrkA mRNA Levels in CD Patients**

<table>
<thead>
<tr>
<th>Clinicopathological feature</th>
<th>NGF mRNA*</th>
<th>TrkA mRNA*</th>
<th>NGF/TrkA mRNA*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of fistulae and/or stenosis</td>
<td>$r=-0.6; p&lt;0.05$</td>
<td>NS</td>
<td>$r=-0.94; p&lt;0.01$</td>
</tr>
<tr>
<td>Duration of disease (y)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Activity index</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Leucocyte level</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>C-reactive protein value</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

*Denominator value.

$r$, coefficient of correlation; NS, not statistically significant.
nerve fibres exert protective effects on gastric mucosa in models of some experimentally induced gastric lesions, and experimentally induced colitis in rats is exacerbated if sensory nerves are disrupted by pretreatment with capsaicin. These observations led to the conclusion that nerves also have modulating functions in intestinal inflammation. In our study we found that in IBD, immune cells, especially mast cells infiltrating the intestinal wall in high numbers, expressed enhanced levels of NGF and TrkA. These findings are of interest because NGF released from these cells may bind to TrkA located in sensory and sympathetic nerves, thereby contributing to nerve activation and remodeling at the site of inflammation. Neural remodelling in chronic intestinal inflammation is characterised by initial axonal degeneration followed by nerve regeneration and sprouting, eventually resulting in successful re- or hyperinnervation. Inasmuch as several steps in wound healing and defence mechanisms are influenced by NGF, successful reinnervation may also be a critical aspect of the healing process and of the recovery of the mucosa in IBD. In fact, NGF released from mast cells in the proximity of the mucosal surface may act as a chemoattractive factor for neutrophils and may activate plasminogen and the classical complement cascade thus inducing fibrinolysis which accelerates the wound healing process.

In addition, our data indirectly suggest a critical role for NGF in the maintenance of mucosal integrity. In fact, in CD patients with high NGF mRNA expression we found a lower rate of intestinal fistulae and/or stenosis, and this association was even more evident in patients in whom concomitant enhanced expression of NGF and TrkA was present. This important aspect is supported by previous experimental data reporting a protective role of NGF and of the enteric nervous system in mucosal defence processes or in the induction of mucosal healing in these disorders. Furthermore, we need to emphasise that we did not analyse other “NGF related factors” such as BDNF and neurotrophin-3. Therefore, we cannot exclude a role for these factors—especially in those patients who exhibited no enhanced NGF and/or TrkA mRNA levels—in the maintenance of surface integrity in the inflamed intestine, as was previously hypothesised in preliminary studies.

The importance of neural structures in inflammation is also underlined in experimental studies where induction of inflammation by intraplantar injection of complete Freund’s adjuvant results in local sensory hypersensitivity and upregulation of NGF but also of neuropeptides such as substance P (SP) and calcitonin gene related peptide (CGRP). A similar pattern of concomitant NGF and neurotransmitter upregulation was observed during the developmental period in rat sensory neurones where NGF regulates tachykinin gene expression and biosynthesis both in vivo and in vitro. In addition, involvement of different neuropeptides such as SP in the pathophysiology of IBD as modulators of immunological responses and as regulators of tissue remodelling is presently under discussion. In fact, recently Mantyh and colleagues reported increased expression of the SP receptor in the enteric neurones of patients with CD and UC, suggesting that SP is also involved in these disorders.

Interactions between nerves and inflammatory cells are not events restricted to chronic inflammation of the intestine. In chronic pancreatitis, an ongoing process of chronic inflammation in the pancreas (axonal damage associated with infiltration of inflammatory cells around enlarged pancreatic nerve bundles) has been reported, similar to damage in CD. In chronic pancreatitis the intensity of the immune cell infiltration in the pancreas correlates with the presence and intensity of abdominal pain.

In conclusion, our findings of the presence of NGF and TrkA in IBD in neural and inflammatory cells further support the hypothesis of a “neuroimmune interaction” in these inflammatory disorders in humans.

This study was supported by the Swiss National Fund’s grant awarded to H Friess (SNF grant 32–49494).


Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease

F F di Mola, H Friess, Z W Zhu, A Koliopanos, T Bley, P Di Sebastiano, P Innocenti, A Zimmermann and M W Büchler

doi: 10.1136/gut.46.5.670

Updated information and services can be found at:
http://gut.bmj.com/content/46/5/670

These include:

References
This article cites 36 articles, 6 of which you can access for free at:
http://gut.bmj.com/content/46/5/670#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Crohn’s disease (932)
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/